Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 590 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PUSH Clear all
Terminated Phase 3 Interventional Results available

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

NCT00322218
View directory record Official record
Conditions
Lymphoma, Large Cell, Diffuse
Interventions
Zevalin
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
60 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 18, 2026, 12:05 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

NCT05902533
View directory record Official record
Conditions
Anal Cancer
Interventions
Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c
Radiation · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 18, 2026, 12:05 PM EDT
Terminated Phase 2 Interventional Results available

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

NCT02419755
View directory record Official record
Conditions
Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Interventions
Bortezomib, Vorinostat, Mitoxantrone, Cytarabine, Methotrexate, Hydrocortisone, Peg-L-Asparaginase, Erwinia L-Asparaginase, Dexamethasone, Mercaptopurine, Doxorubicin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Not applicable Interventional

Managing Pain in Patients With MTP Arthritis

NCT04833608
View directory record Official record
Conditions
Hallux Rigidus
Interventions
Vktory insoles, Morton's extension insoles
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis

NCT00001586
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Rituximab, Fludarabine phosphate, Leukemic or stroma cells
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Not applicable Interventional Results available

Use of Joystick-operated Ride-on-toys to Improve Affected Arm Use and Function in Children With Hemiplegic Cerebral Palsy

NCT05559320
View directory record Official record
Conditions
Hemiplegic Cerebral Palsy
Interventions
Ride-on-toy navigation training, Upper extremity functional training
Device · Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
3 Years to 8 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Testing and Vaccine Literacy for Women With Criminal Legal System Involvement

NCT05582746
View directory record Official record
Conditions
COVID-19 Pandemic
Interventions
Tri-City COVID Attitudes Study
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 18, 2026, 12:05 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

NCT04037605
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Phase 1 Interventional Results available

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

NCT03792256
View directory record Official record
Conditions
Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
Interventions
Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 31 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 18, 2026, 12:05 PM EDT
Not listed Phase 1Phase 2 Interventional

AMES Treatment of the Impaired Leg in Chronic Stroke Patients

NCT01378637
View directory record Official record
Conditions
Stroke, Cerebrovascular Accident, Hemiparesis
Interventions
AMES- Leg treatment
Device
Lead sponsor
AMES Technology
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 18, 2026, 12:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Media Parenting Prevention Intervention

NCT05332275
View directory record Official record
Conditions
Substance Related Problem
Interventions
Intervention Arm - T.E.C.H. Parenting, Control Arm - General Positive Parenting
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 14 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Not applicable Interventional Results available

Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS

NCT02276066
View directory record Official record
Conditions
Sepsis
Interventions
GFR by Iohexol, Urine Collection, Blood samples
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Phase 2 Interventional Results available

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL

NCT00074282
View directory record Official record
Conditions
Leukemia
Interventions
rituximab, cyclophosphamide, pentostatin, Alemtuzumab
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
143
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 112 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women

NCT02272647
View directory record Official record
Conditions
Healthy
Interventions
IM Saline Placebo (0.25 ml), IM Estradiol valerate (2.5 mg), IM Saline Placebo (0.5 ml), IM Estradiol valerate (5.0 mg), Oral Micronized Progesterone, Oral Placebo, Ghrelin (0.3 ug/kg), Medroxyprogesterone - Acetate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Not applicable Interventional

Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

NCT02470299
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Ketorolac, Placebo
Drug · Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 18, 2026, 12:05 PM EDT
Recruiting Phase 2Phase 3 Interventional

Impact of Brief Daily Functional Resistance Training on Lower Extremity Physical Performance

NCT06396247
View directory record Official record
Conditions
Mobility Limitation
Interventions
Functional Activity Strength Training
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Not applicable Interventional Results available

Self-Management App for Patients With Left-Ventricular Assist Devices

NCT03049748
View directory record Official record
Conditions
Heart Failure
Interventions
Mobile phone app (VAD Care App), Usual LVAD Care
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
St Louis, Missouri • Lincoln, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

NCT02935699
View directory record Official record
Conditions
Acute Urticaria
Interventions
Test Drug (JDP-205), Active Control (Diphenhydramine)
Drug
Lead sponsor
JDP Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Not applicable Interventional

Targeted Multidomain (T-MD) Interventions for Complex Mild Traumatic Brain Injury (mTBI)

NCT04549532
View directory record Official record
Conditions
Concussion, Mild
Interventions
Targeted Multidomain, Behavioral Management
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 49 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 18, 2026, 12:05 PM EDT
Withdrawn No phase listed Observational

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

NCT01973517
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Feraheme, Gadolinium-based contrast
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 18, 2026, 12:05 PM EDT
Not yet recruiting Not applicable Interventional

Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial

NCT07606313
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Cancer, Functional Limitation
Interventions
Functional Resistance Training, Stretching, Delayed Functional Resistance Training
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 18, 2026, 12:05 PM EDT
Recruiting Not applicable Interventional

Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy

NCT06591780
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetes Mellitus
Interventions
Clinical Evaluation, Plantar Pressure Biofeedback Gait Training, Propulsion Biofeedback Gait Training
Other
Lead sponsor
Florida Institute for Human and Machine Cognition
Other
Eligibility
45 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 18, 2026, 12:05 PM EDT
Completed Not applicable Interventional Results available

Prevention Interventions for Opioid Misuse

NCT04550715
View directory record Official record
Conditions
Opioid Use
Interventions
Brief intervention (BI), Portal, Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 30 Years
Enrollment
1,155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 18, 2026, 12:05 PM EDT